Video

There's been much controversy concerning embryonic stem cell research in recent years. However, a new study finds some patients are benefitting from ADULT stem cell therapy right now, and doctors hope we are one step closer to some major breakthroughs... Dr. Sean Kenniff reports... Donald Reid is hoping adult stem cells will give him more time. (Donald Reid/Heart Patient) THERE'S NOT MANY OPTIONS LEFT FOR ME. The 57-year-old has clogged arteries and heart disease so bad he's not a candidate for surgery. Instead he's joined an experimental study that involves this machine. It's taking his blood and pulling out stem cells. We're not talking about stem cells from an embryo. These are Donald's own adult stem cells. In the coming days doctors will inject them directly into Donald's heart… with the hope it will regenerate and revitalize the damaged organ. (Dr. Sean Kenniff/CBS NEWS) Adult stem cells have become standard therapy for treating several types of cancers like lukemia and lymphoma. But according to new research this treatment is now starting to show real promise in treating other diseases. A review of hundreds of trials found in some patients adult stem cells have stopped auto-immune diseases like rheumatoid arthritis and multiple sclerosis. Some heart patients like Donald have also seen improvement. Weill Cornell's Michael Schuster is excited by the results but warns it's still early. (Dr. Michael Schuster/NY Pres., Weill Cornell Med. Ctr.) WE DON'T KNOW YET WHAT THE BEST TECHNIQUE IS, WE DON'T REALLY KNOW HOW MUCH OF A BENEFIT THE PATIENTS WILL HAVE. And when it comes to diseases like Diabetes, Alzheimer's and Parkison's. (Dr. Michael Schuster/NY Pres., Weill Cornell Med. Ctr.) I THINK WE'RE STILL A FEW YEARS AWAY FROM KNOWING WHETHER STEM CELLS REALLY TURN OUT TO BE THE ANSWER. Donald should have an answer much sooner. His wish….. (Donald Reid/Heart Patient) TO BE LIKE EVERYONE ELSE AND NOT HAVE TO WORRY ABOUT THAT MY HEART MIGHT GIVE OUT. In the coming weeks he'll know if that wish came true. Doctor Sean Kenniff, CBS News.